Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799741 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
A Phase 2 study of DENV-3 Controlled Human Infection Model, sponsored by AbViro.
- Active
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 3
- Study locations
NCT06799741 is a Phase 2 study of DENV-3 Controlled Human Infection Model that is active but no longer recruiting, run by AbViro. The registered enrollment target is 85 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT06799741, a Phase 2 study of DENV-3 Controlled Human Infection Model, is active but no longer recruiting, sponsored by AbViro.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AV-1 100 mg
- DRUG AV-1 300 mg
- DRUG AV-1 900 mg
Study Locations (3)
Maryland
- Center for Immunization Research (CIR) JHBSPH - Baltimore
- Center for Immunization Research Inpatient Unit - Baltimore
Vermont
- UVM Larner College of Medicine Department of MMG - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2026-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06799741
The ClinicalTrials.gov registry entry for NCT06799741 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbViro, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with DENV-3 Controlled Human Infection Model appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06799741 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Vermont.
Frequently Asked Questions
What is clinical trial NCT06799741 about?
NCT06799741 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection". The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
What is the current status of trial NCT06799741?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2025-01-07. Estimated completion is 2026-03-14.
What conditions does trial NCT06799741 study?
This clinical trial studies the following conditions: DENV-3 Controlled Human Infection Model.
What interventions are being tested in trial NCT06799741?
The interventions under investigation include: Placebo (DRUG), AV-1 100 mg (DRUG), AV-1 300 mg (DRUG), AV-1 900 mg (DRUG).
Who is sponsoring clinical trial NCT06799741?
This trial is sponsored by AbViro, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799741 being conducted?
This trial has 3 study locations across Maryland, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.